Tuberculosis has attracted increased attention worldwide due to its high morality and its resistance to treatment with traditional antibacterial drugs. The L,D-transpeptidase LdtMt2 confers resistance to traditional b-lactams and is considered a target for anti-Tuberculosis treatment. Carbapenems are pro posed to inhibit Mycobacterium tuberculosis by repressing the activity of LdtMt2. The interaction mech anisms between LdtMt2 and carbapenems have been revealed by LdtMt2-carbapenem adduct structures along with various biochemical assays. Interestingly, the lack of the 1-b-methyl group in imipenem may be related to its high binding ability to LdtMt2. However, there is limited evidence on the interaction mode of LdtMt2 and panipenem, another carbapenem lacking the 1-b-methyl group. Herein, we identified the biochemical features of panipenem binding to LdtMt2. We further suggest that the presence of the 1-b-methyl group in carbapenems is indeed related to the ligand affinity of LdtMt2 and that the presence of the Y308 and Y318 residues in LdtMt2 stabilized the conformation of the LdtMt2-carbepenem adduct. Our research provides a structural basis for the development of novel carbapenems against
L,D transpeptidases.


Dr. Kai Deng received his Bachelor degree from Wuhan University in 2007 and PhD from Chinese Academy of Sciences in 2012, respectively. Since 2012, he has been a faculty member as a Lecturer (2012-2014) and Associate Professor (2014-2020) in Hubei University of Medicine. Currently, he is the Director of department of Biological Sciences. He served for the Expert Evaluation Committee for the National
Natural Science Foundation of China. He won the honor of Chutian scholar in Hubei Province in 2018.